Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Milestone Pharmaceuticals ( (MIST) ) has provided an announcement.
Milestone Pharmaceuticals reported its first quarter 2025 financial results and provided updates on its regulatory and corporate activities. The company is addressing Chemistry, Manufacturing, and Controls (CMC) issues raised by the FDA regarding its lead product, CARDAMYST, for PSVT, and has requested a Type A meeting with the agency. Despite these challenges, the company remains optimistic about CARDAMYST’s potential, highlighted by a new patent extending its protection until 2042 and positive feedback from a survey of managed care professionals. Financially, Milestone reported no revenue for the quarter, with increased expenses due to higher consulting and regulatory costs.
The most recent analyst rating on (MIST) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Milestone Pharmaceuticals stock, see the MIST Stock Forecast page.
Spark’s Take on MIST Stock
According to Spark, TipRanks’ AI Analyst, MIST is a Underperform.
Milestone Pharmaceuticals’ overall stock score reflects substantial financial difficulties, including no revenue and negative cash flows. However, the upcoming launch of CARDAMYST provides a potential turnaround opportunity, which is a significant positive factor. Technical indicators suggest a bearish trend, and valuation metrics highlight the lack of earnings and dividends, indicating a speculative investment.
To see Spark’s full report on MIST stock, click here.
More about Milestone Pharmaceuticals
Milestone Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative cardiovascular medicines. Their primary product, CARDAMYST, is an investigational therapy aimed at treating paroxysmal supraventricular tachycardia (PSVT), with a focus on providing a self-administered solution for rapid termination of episodes.
Average Trading Volume: 2,635,522
Technical Sentiment Signal: Sell
Current Market Cap: $64.16M
Find detailed analytics on MIST stock on TipRanks’ Stock Analysis page.